IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Advanced Ovarian Carcinoma
OHSU Knight Cancer Institutemonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
244 Active assets in the Advanced Ovarian Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trabectedin AGO Research GmbH | Phase 4 | BBB |
Mirvetuximab Soravtansine AstraZeneca | Phase 3 | BBB |
Olaparib Imunon | Phase 4 | BB |
Irinotecan OHSU Knight Cancer Institute | Phase 2 | BB |
Carboplatin University of Washington | Phase 3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →